"10.1371_journal.pone.0060507","plos one","2013-03-25T00:00:00Z","Kihyuck Kwak; Rosie Jiang; Subhashini Jagu; Joshua W Wang; Chenguang Wang; Neil D Christensen; Richard B S Roden","Department of Pathology, Johns Hopkins University, Baltimore, Maryland, United States of America; Department of Biostatistics, Johns Hopkins University, Baltimore, Maryland, United States of America; Departments of Pathology, Microbiology and Immunology, Penn State University, Hershey, Pennsylvania, United States of America","Conceived and designed the experiments: KK, NDC, RBSR. Performed the experiments: KK, RJ, SJ, JWW. Analyzed the data: CW, KK, RJ, SJ, JWW, RBSR. Contributed reagents/materials/analysis tools: KK, CW, NDC, RBSR. Wrote the paper: KK, CW, NDC, RBSR.","The authors have read the journals policy and have the following conflicts. Subhashini Jagu and Richard Roden are co-inventors on L2 patents (20090047301 Papillomavirus L2 N-Terminal Peptides for the Induction of Broadly Cross-Neutralizing Antibodies and 20100297144 MULTITYPE HPV PEPTIDE COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF HUMAN PAPILLOMAVIRUS INFECTION) licensed to Shantha Biotechnics Ltd., GlaxoSmithKline, PaxVax, Inc. and Acambis, Inc and have received research funding from Shantha Biotechnics Ltd., Sanofi Pasteur and GlaxoSmithKline and Richard Roden is a founder of Papivax LLC. The terms of these arrangements are managed by Johns Hopkins University in accordance with its conflict of interest policies. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2013","03","Kihyuck Kwak","KK",7,TRUE,3,4,6,4,FALSE,FALSE,TRUE,5,"1;2;3;5;6",TRUE
